Official Title
Prospective Assay for SARS-CoV-2 Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method
Brief Summary

Prospective assay for SARS-CoV-2 antibody detection indirectly by immunofluorescence: SARS-CoV2 IIF method

Detailed Description

Sample preparation, serum separation by centrifugation

- 100 µl of serum for standard SARS-CoV2 ELISA is used according to the instructions for
use.

- 100 µl of serum indirect immunofluorescent (IIF) method is used, the samples thus
prepared analysis is performed under an automated microscope

Unknown status
SARS-COV2

Diagnostic Test: Immunfluorescence

Serum indirect immunofluorescent (IIF) method is used, analysis is performed under an automated microscope.

Eligibility Criteria

Inclusion Criteria:

- Person over 18 years of age

- Signing a package leaflet and a informal consent

- In the case of a positive group, confirmed by SARS-CoV2 qPCR Patient with COVID-19 or
recovered individual.

- In case of negative group by SARS-CoV2 qPCR test 2 negative in COVID-19 suffering
individual

Exclusion Criteria:

- Refuses to sign the consent form

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Hungary
Locations

University of Szeged, Albert Szent-Györgyi Health Center
Szeged, Hungary

Investigator: Katalin Burián, MD
Contact: +36 62 544 000

Contacts

Katalin Burián, MD
+36 62 544 000
burian.katalin@med.u-szeged.hu

Dávid Pintér, Pharm. D.

Katalin Burián, MD, Principal Investigator
University of Szeged, Institute of Clinical Microbilogy

Bilogical Research Centre, Szeged
NCT Number